Description:

SOUTHWEST ONCOLOGY GROUP S0221 SUPPLEMENTARY FOLLOW UP FORM Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=BACD42B3-A5E1-6833-E034-0003BA12F5E7

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=BACD42B3-A5E1-6833-E034-0003BA12F5E7

Keywords:
Versions (3) ▾
  1. 8/26/12
  2. 1/9/15
  3. 9/20/21
Uploaded on:

September 20, 2021

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Breast Cancer NCT00070564 Follow-Up - SOUTHWEST ONCOLOGY GROUP S0221 SUPPLEMENTARY FOLLOW UP FORM - 2101304v3.0

No Instruction available.

  1. StudyEvent: SOUTHWEST ONCOLOGY GROUP S0221 SUPPLEMENTARY FOLLOW UP FORM
    1. No Instruction available.
Header
Header
Has the patient been diagnosed with opposite breast cancer since submission of last follow-up form?
Has the patient been diagnosed with first local-regional recurrence since submission of last follow-up form?
Site(s) of First Local-Regional Progression (select all that apply)
How was this progression information obtained?
How was this progression information obtained?
Has the patient been diagnosed with first distant recurrence/progression since submission of last follow-up form?
Site(s) of First Distant Progression
Comments

Similar models